|
WO2021005955A1
|
|
Medical image guidance marker
|
|
JP2020183950A
|
|
Marker for evaluating risk of reduction in the amount of muscle
|
|
WO2020213699A1
|
|
Determination method of autoimmune disease and/or inflammatory disease, and preventive and/or therapeutic agent of inflammatory disease and/or autoimmune disease
|
|
WO2020111249A1
|
|
Therapeutic agent of peripheral blood flow disorder
|
|
JP2020073483A
|
|
Corneal endothelium ecm therapeutic drug
|
|
WO2020080451A1
|
|
Inhibitor of renal fibrosis in diabetic nephropathy
|
|
WO2020045488A1
|
|
Porous scaffold material for three-dimensional cell culture use and method for producing same
|
|
WO2020009248A1
|
|
Composition for inhibiting fibrosis in ocular tissue
|
|
JP2020200247A
|
|
Compound, pharmaceutical composition, kdm5c inhibitor and antidepressant
|
|
JP2019152671A
|
|
Method of detecting colorectal cancer
|
|
JP2019192219A
|
|
Device and program for determining ability of property management and recording medium
|
|
WO2019139031A1
|
|
Nutrient liquid cultivation method for cultivated plant, and culture solution for nutrient liquid cultivation
|
|
JP2020105124A
|
|
Agent for preventing or treating functional gastrointestinal disorder and abdominal pain after colonoscopy
|
|
JP2020085607A
|
|
Nucleolus fluorescent dyeing method, nucleolus fluorescent dyeing liquid, cancer cell detection liquid and optical microscope
|
|
US2020254101A1
|
|
Two-drug type local injection solution for submucosal injection
|
|
US2020367743A1
|
|
Method for dynamic evaluation of tear fluid layer and device therefor
|
|
JP2019011314A
|
|
Regulatory t-cell inducer, adjuvant and food composition
|
|
JP2018138621A
|
|
Corneal endothelium ecm therapeutic drug
|
|
WO2018212192A1
|
|
Method and marker for estimating prognosis and/or metastasis potential of cancer
|
|
WO2018203515A1
|
|
Method and device for evaluating lacrimal fluid layer dynamics
|
